Why was the EPS miss so large when revenue was close to guidance?

Revenue of $890.3M landed within management's own $880M–$900M guidance range, so the miss was consensus-driven rather than operational. The $0.20 GAAP EPS miss points to elevated costs — likely marketing, fulfillment, stock-based compensation, or GLP-1 product-related expenses — rather than a revenue collapse.

What forward guidance should traders watch most closely?

Any change to the full-year 2026 revenue guidance of $3.1B–$3.3B or adjusted EBITDA guidance of $275M–$325M is the pivotal catalyst; a reaffirmation could stabilize the stock, while a cut would likely extend the selloff.

Are other healthcare or telehealth stocks at risk of contagion?

Telehealth-adjacent names and consumer-health platforms may see sentiment pressure, but large-cap pharma such as Novo Nordisk and AbbVie are insulated by pipeline-driven valuations. The Russell 2000 is the most relevant index to monitor for broader small/mid-cap healthcare impact.

What are the key price levels for HIMS traders to watch?

The session low of $20.69 is immediate support; a sustained break below it on volume would signal continued distribution. The $24.00 area is near-term resistance — a recovery above it would require positive guidance commentary from management.

HIMSHims & Hers Health, Inc. · 800x지금 거래하기

빠른 링크

Hims & Hers Q3 2026 Earnings Miss: GAAP EPS -$0.14 Misses by $0.20 — Leveraged HIMS CFD Traders Face -12.75% Overnight Drop

발행됨: 2026-11-09 21:40:24 UTC

HIMS 지금 거래하기레버리지 800x

HIMS

보기 HIMS 페이지

데이터 스냅샷

Price

$22.58

24h Low

$20.69

24h High

$26.27

GAAP EPS

-$0.14

24h Change

-12.75%

HIMS Price

$22.58

Q3 Revenue

$890.3M

24h Change (%)

-12.75%

EPS vs. Consensus

-$0.20

Revenue vs. Consensus

-$2.47M

주요 요점

•HIMS GAAP EPS of -$0.14 missed consensus by $0.20 — an unusually large profitability gap relative to a minor $2.47M revenue shortfall, signaling operating cost pressure.
•Leverage risk is acute: at 50x, the -12.75% price drop equates to a ~65% margin loss on a pre-earnings long position opened near $26.00.
•Revenue grew 48.6% YoY and landed within management's own $880M–$900M guidance range, providing a potential floor if full-year guidance is reaffirmed.
•Cross-market spillover is limited — this is an idiosyncratic event, though telehealth-adjacent healthcare names may see sympathy pressure.
•The $20.69 intraday low is the key support level; a sustained break lower on volume would signal distribution rather than a one-session earnings reaction.

Leverage map for Hims & Hers Health, Inc. (HIMS), a stock, showing 25 candles. The chart’s primary price opened at $25.8785, reached a high of $26.275 and a low of $20.69, and closed at $22.505, down 13.04% over 24 hours. The short-position reference entry is $22.505. Leverage tiers are 10×, 50×, and 800×; the chart summary does not provide liquidation prices, so none are stated. The displayed move shows a sharp decline from the open to the close, with the session low $1.815 below the closing price. The pulse headline attributes the drop to a Q3 2026 earnings miss and cites GAAP EPS of -$0.14, missing estimates by $0.20, and an overnight decline of 12.75%. Those headline figures differ from the chart’s 24-hour change of -13.04%; the chart value is reported here as supplied. No related assets or cross-market comparisons are included. — HIMS closed at $22.505, down 13.04% over 24 hours; short-entry reference: $22.505, with 10×, 50×, and 800× leverage tiers.

According to Seeking Alpha and investor relations filings, Hims & Hers Health reported Q3 2026 GAAP EPS of -$0.14, missing consensus by $0.20, and revenue of $890.3 million, missing consensus by $2.47

Event Summary

According to Seeking Alpha and investor relations filings, Hims & Hers Health reported Q3 2026 GAAP EPS of -$0.14, missing consensus by $0.20, and revenue of $890.3 million, missing consensus by $2.47 million. Results were published on November 9, 2026. Despite the estimate misses, revenue grew approximately 48.6% year over year, and the $890.3 million result landed within management's own guidance range of $880 million–$900 million. The company had previously raised full-year 2026 revenue guidance to $3.1 billion–$3.3 billion and adjusted EBITDA guidance to $275 million–$325 million following Q2. The critical unresolved question is whether the GAAP loss reflects one-time cost items — marketing, fulfillment, stock-based compensation — or a structural erosion of operating leverage as the company scales its GLP-1 and telehealth verticals.

Leverage Impact Analysis

HIMS stock is currently trading at $22.58, down 12.75% on the session, with an intraday low of $20.69 against a 24-hour high of $26.27 — a range of $5.58, or approximately 21% peak-to-trough volatility. This is the leverage environment traders are navigating.

Long CFD scenario: A trader who opened a 50x long HIMS CFD at $26.00 (pre-earnings) now faces a mark-to-market loss of approximately $3.42 per share. At 50x leverage, that translates to roughly a 65.8% loss on initial margin — a near-wipeout without a stop-loss in place. At 20x leverage, the same move represents a 26.3% margin loss, still severe within a single session.

Short CFD scenario: A trader with a 20x short opened at $24.00 (anticipating a miss) has seen a favorable move to $22.58 at current prices — a 5.9% gain on the underlying, equating to roughly 118% return on initial margin at 20x. However, the intraday bounce from $20.69 to $22.58 means shorts opened intraday near the low face snap-back risk.

The EPS miss magnitude ($0.20 vs. consensus) is unusually large relative to the small revenue shortfall ($2.47 million), flagging profitability risk as the dominant driver of volatility. Traders should monitor after-hours management commentary on operating leverage and cost structure before sizing new positions. Check current funding rates on CoinUnited.io for real-time positioning costs.

Cross-Market Impact

This is a largely idiosyncratic equity event with limited macro spillover. The primary cross-market read-through is to the telehealth and consumer-health sector. Stocks such as AbbVie Inc., Novo Nordisk A/S, and HCA Healthcare, Inc. may see marginal sentiment pressure if investors question the broader patient-acquisition economics in digitally-enabled healthcare. AstraZeneca PLC and Amgen Inc. are insulated given their pipeline-driven valuations, but any compounding or GLP-1 supply commentary from management could trigger read-throughs.

The Russell 2000 Index is the most relevant index exposure: HIMS is a mid-cap growth name, and a cluster of growth-health misses can weigh on small/mid-cap healthcare allocations. Macro assets — DXY, gold, BTC — are not materially affected by this result.

Trading Considerations

Key levels to monitor: $20.69 (session low / near-term support), $22.58 (current price), and $26.27 (session high / pre-earnings reference). A close below $20.69 on volume would suggest the selloff is distribution-driven rather than a knee-jerk reaction. Conversely, a recovery above $24.00 would require positive forward guidance revision or a credible explanation of the GAAP loss drivers.

The persistence of this move depends entirely on management commentary: if full-year guidance is maintained at $3.1B–$3.3B revenue and $275M–$325M adjusted EBITDA, the market may treat the EPS miss as noise. Any guidance cut would likely extend the selloff and compress valuation multiples across the biotech and digital-health pipeline space.

Trade Hims & Hers Health, Inc. on CoinUnited.io

Trade HIMS with up to 800x leverage → | Create Free Account

_Availability and maximum leverage depend on product, jurisdiction and account eligibility. Leverage amplifies losses and positions can be liquidated._

자주 묻는 질문

A 50x long opened at $26.00 faces approximately a 65.8% margin loss at the current $22.58 price — positions without stop-losses are at high risk of liquidation. At 20x leverage, the same move represents a 26.3% margin drawdown.